Back to Results

A Double-Blind Study to Evaluate the Efficacy and Safety of BMN 110 in Patients With Mucopolysaccharidosis IVA (Morquio A Syndrome)

Interested in this Trial?

Contact Us

Trial Status Completed

Trial Identifier

NCT01275066

Condition

MPS IVA, MPS IV A

The below information is taken directly from public registry websites such as ClinicalTrials.gov, EuClinicalTrials.eu, ISRCTN.com, etc. and has not been edited.

Trial Summary

This Phase 3 study will evaluate the efficacy and safety of 2.0 mg/kg/week BMN 110 and 2.0 mg/kg/every other week BMN 110 in patients with mucopolysaccharidosis IVA (Morquio A Syndrome).

There is currently no standard accepted treatment for MPS IVA other than supportive care. Enzyme replacement therapy (ERT) may be a potential new treatment option for MPS IVA patients. BMN 110 is administered to MPS IVA patients by IV infusion, allowing cellular uptake by the mannose-6-phosphate receptor and transportation to the lysosomes.

This enzyme uptake into the lysosomes is hypothesized to promote increased catabolism of keratan sulfate (KS) in tissue macrophages, hyaline cartilage, other connective tissues, and heart valve, and reduce the progressive accumulation of KS which is responsible for the clinical manifestations of the disorders.

Eligibility Criteria

Birth Sex

All

Age

From 5 Years

Healthy Volunteers

No

Drug/Treatment:

BMN 110 Weekly, Placebo, BMN 110 Every Other Week

Phase:

Phase 3

Study Type:

Interventional

Number of Participants:

177

Study Started:

2011-02

Study Updated:

2014-07-07

Trial Locations

  • Oakland, California, United States

  • Wilmington, Delaware, United States

  • Washington, District of Columbia, United States

  • Chicago, Illinois, United States

  • New York, New York, United States

  • Seattle, Washington, United States

  • Cordoba, , Argentina

  • Campina Grande, , Brazil

  • Porto Alegre, , Brazil

  • Montreal, , Canada

  • Sherbrooke, , Canada

  • Toronto, , Canada

  • Bogota, , Colombia

  • Copenhagen, , Denmark

  • Lyon, , France

  • Paris, , France

  • Mainz, , Germany

  • Monza, , Italy

  • Tokyo, , Japan

  • Seoul, , Korea, Republic of

  • Amsterdam, , Netherlands

  • Coimbra, , Portugal

  • Doha, , Qatar

  • Riyadh, , Saudi Arabia

  • Taipei, , Taiwan

  • Birmingham, , United Kingdom

  • London, , United Kingdom

  • Manchester, , United Kingdom

Inclusion Criteria

  • At least 5 years of age.
  • Documented clinical diagnosis of MPS IVA based on clinical signs and symptoms of MPS IVA and documented reduced fibroblast or leukocyte GALNS enzyme activity or genetic testing confirming diagnosis of MPS IVA.
  • Willing and able to provide written, signed informed consent, or in the case of patients under the age of 18 (or 16 years, depending on the region), provide written assent (if required) and written informed consent by a legally authorized representative after the nature of the study has been explained, and prior to any research-related procedures.
  • Must meet the study entrance requirements for the 6-minute walk test.
  • Sexually active patients must be willing to use an acceptable method of contraception while participating in the study.
  • Females of childbearing potential must have a negative pregnancy test at Screening and be willing to have additional pregnancy tests during the study.

Exclusion Criteria

  • Previous hematopoietic stem cell transplant (HSCT).
  • Previous treatment with BMN 110.
  • Has known hypersensitivity to any of the components of BMN 110.
  • Major surgery within 3 months prior to study entry or planned major surgery during the 24-week treatment period.
  • Pregnant or breastfeeding at Screening or planning to become pregnant (self or partner) at any time during the study.
  • Use of any investigational product or investigational medical device within 30 days prior to Screening, or requirement for any investigational agent prior to completion of all scheduled study assessments.
  • Concurrent disease or condition, including but not limited to symptomatic cervical spine instability, clinically significant spinal cord compression, or severe cardiac disease that would interfere with study participation or safety as determined by the Investigator.
  • Any condition that, in the view of the Investigator, places the patient at high risk of poor treatment compliance or of not completing the study

Contact BioMarin Clinical Trials

Please complete and submit the following form to express interest in participating and request more information about one of our clinical trials.

By completing this form and clicking the send button, you understand and hereby consent to storage of your personal information, including within the United States and Europe, which will be accessible by BioMarin for purposes such as responding to your request, quality control, fulfilling compliance obligations, and assisting with products, services, or clinical trials. Depending on where you live, you may have the right to request access to, removal, or correction of your personal information held by BioMarin. You may submit your request via the contact information and/or webform located within the full BioMarin Privacy Policy.

*required fields

"*" indicates required fields

This field is hidden when viewing the form
This field is hidden when viewing the form

What’s Next?

Visit the following links to learn more about clinical trials.

Discuss this trial with your care team.

You may wish to print this page to share the details with your healthcare providers and discuss whether you may be eligible.

Print

Get in touch.

Contact Us